Users should refer to the original published version of the material for the full abstract. No warranty is given about the accuracy of the copy. However, users may print, download, or email articles for individual use. Use the geographic coordinates of the company location: 45.734945. Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. If you want to reach it, go to the address: Avenue Jean Mermoz 47, 69008 Lyon, France.A detailed analysis of the medical pathways is necessary in order to identify the medical and territorial determinants and their impact on the patient's outcome. HOPITAL PRIVE JEAN MERMOZ is a Hospital and Health Care company located in 55 Av. This study highlights that a significant number of patients with PDAC are still operated in low-volume centers or do not receive any specific oncological treatment. The 1-year survival rate was 47% in the overall population. Less than half of patients were operated in a high-volume center, defined by more than 20 PDAC resections performed annually, mainly university hospitals. Within the follow-up period, 353 (18.9%) were operated with a curative intent, 743 (39.7%) underwent chemo- and/or radiotherapy, and 776 (41.4%) did not receive any of these treatments. A total of 1872 patients met inclusion criteria corresponding to an incidence of 22.6 per 100,000 person-year. We used the national hospital discharge summaries database system to analyze the management of patients with newly diagnosed PDAC over the year 2016 in Auvergne-Rhône-Alpes region (AuRA) (France). Hôpital privé Jean Mermoz est un service de Soins de Suite et de Réadaptation, qui est basé à Lyon 08, dont le code postal est 69008. Our purposes were to describe the medical path of PDAC patients in the real-life setting and evaluate the overall survival at 1 year. Pancreatic ductal adenocarcinoma (PDAC) remains a major public health challenge, and faces disparities and delays in the diagnosis and access to care. A deeper analysis of the medical pathway for pancreatic adenocarcinomas patients is ongoing in order to suggest adapted public health measures. We pointed out, in a large patient population (n = 1872), the inverse correlation between the level of expertise of the health facility in which the patient had his first hospital stay and the likelihood of undergoing any specific treatment for PDAC. We decided to assess in our region, over 1 year (2016), the real-life pancreatic cancer's management by the analysis of French hospital discharge summaries database system. Furthermore, disparities in the access to care (often participating in late diagnosis) have been described in demographic, clinical, and/or socioeconomic factors. Despite significant therapeutic progress, the five-year survival after diagnosis remains poor. Abstract: Simple Summary: With an increasing incidence, late diagnosis, and high mortality rate, pancreatic adenocarcinoma remains, in 2021, a real challenge for health institutions and professionals worldwide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |